Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

Who May Qualify: - Provided willing to sign a consent form to participate in the study; - Aged 18 years or older; - Fulfilled the 2019 EULAR/ACR classification criteria for SLE at the time of study entry; - Prescribed anifrolumab for SLE treatment for the first time, according to the approved Italian label and reimbursement criteria; Who Should NOT Join This Trial: - Patients who are at LLDAS5 at the time of study entry; - Previous exposure to anifrolumab; - Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy \[mycophenolate mofetil (MMF)/cyclophosphamide (CYC) + high dose steroids\], isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus - Currently participating in any interventional clinical trial with an investigational product; - Inability to understand and sign the willing to sign a consent form and to fill in patient questionnaires Always talk to your doctor about whether this trial is right for you.